Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
URGN Stock Chart & Stats
$20.10
-$0.02(-0.18%)
At close: 4:00 PM EST
$20.10
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$3.42 - $30.00
Previous CloseN/A
Volume157.75K
Average Volume (3M)678.32K
Market Cap
$964.26M
Enterprise Value$1.08B
Total Cash (Recent Filing)$127.03M
Total Debt (Recent Filing)$129.94M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 12, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding46,808,890
10 Day Avg. Volume632,824
30 Day Avg. Volume678,316
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-51.87
Price to Sales (P/S)5.05
P/FCF Ratio-4.70
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue14.97
Enterprise Value/Gross Profit16.85
Enterprise Value/Ebitda-11.88
Forecast
1Y Price Target
$36.00Price Target Upside79.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn 88.5% gross margin signals durable product-level pricing power and low cost of goods sold for UroGen’s portfolio. High gross margins provide structural capacity to fund R&D and commercial expansion, improving odds of reaching profitability as sales scale over the next 2–6 months.
JELMYTO Revenue MomentumConsistent year-over-year growth in JELMYTO revenue demonstrates commercial traction and repeatable demand in the core bladder cancer market. Durable product revenue growth supports reinvestment in sales and market access, underpinning near-term revenue stability and scaling potential.
ZUSDURI Reimbursement & AccessPermanent J-code plus broad payer access (95% covered lives) is a structural improvement to reimbursement and billing clarity. This removes a key commercialization headwind, enabling steadier adoption in community settings and sustaining durable uptake over the next several quarters.
Bears Say
Negative Equity And High LeverageNegative equity and heavy leverage indicate structural balance-sheet fragility that limits financing flexibility. This elevated solvency risk makes the company more dependent on external funding for operations and strategic initiatives, raising execution risk over the medium term.
Negative Operating Cash FlowPersistent negative operating cash flow shows the business is not yet self-funding its losses. Reliance on external financing or equity raises dilution and refinancing risk, constraining ability to invest in commercialization or trials if market conditions tighten over the coming months.
Rising Expenses And Widening Net LossHigher SG&A tied to ZUSDURI commercialization and an expanding sales force has materially increased cash burn, widening net losses. If revenue ramps slower than planned, elevated operating costs could pressure margins and delay the path to sustainable profitability in the 2–6 month horizon.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $30.00 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $964.26M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 21 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 06, 2025. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.002.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.5.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,808,890 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 21.906%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (79.10% Upside)
$36.00 (79.10% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 34.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.71%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong progress in the ZUSDURI launch and JELMYTO revenue growth, offset by challenges in operational execution and increased expenses. The permanent J-code for ZUSDURI is anticipated to drive future growth, but current operational delays and increased net loss are notable concerns.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$36.00
▲(79.10% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.03% Insiders
5.38% Mutual Funds
13.09% Other Institutional Investors
70.61% Public Companies and
Individual Investors